GlassScriptPhysician profile
Katelyn M Squire
NPI 1992114680
$705.92
in general payments reported to CMS, 2019-2025
15 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $187 · 2023: $134 · 2024: $133 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $145.85 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $109.84 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Ironshore Pharmaceuticals INC. | $91.12 | 2023-2024 | Jornay Pm |
| Kaleo, INC. | $66.59 | 2021-2022 | |
| Pfizer INC. | $53.90 | 2022-2023 | |
| Cranial Technologies, INC | $50.28 | 2021-2025 | Doc Band |
| Seqirus USA INC | $37.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $23.87 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $21.97 | 2021 | |
| Neos Therapeutics, LP | $21.34 | 2025 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $20.78 | 2021 | |
| Biogen, INC. | $17.68 | 2025 | Spinraza |
| Tris Pharma INC | $15.72 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $14.84 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.53 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Squire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.